After validating YAP and TAZ expression (Figure 5D), we performed a dose-response assay with belinostat, showing that constitutively active YAP or TAZ is capable of raising belinostat IC50 in IDHmut glioma cells to a level comparable with most IDHwt GBM cells (Figure 5, E and F). This evidence concerns the gene YAP1 and central nervous system cancer.